ReviewJournal of gastroenterology2012
Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances.
Review in Journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.Neuroendocrinology · 2016Guideline
- Current Medical Controversies in Zollinger-Ellison Syndrome.Biomedicines · 2025Review
- Sunitinib induced glomerular thrombotic microangiopathy in a patient with refractory pancreatic neuroendocrine tumour.Journal of clinical pathology · 2025Article
- Evaluation of the Real-Life Efficacy and Safety of the Treatment with Lutetium-177 Dotatate for Metastatic Neuroendocrine Tumors.Journal of clinical medicine · 2025Article
- Case Report: PRRT in a patient with Zollinger-Ellison syndrome. The management of gastrointestinal complications.Frontiers in oncology · 2025Article
- Long-Term Proton Pump Inhibitor-Acid Suppressive Treatment Can Cause Vitamin BInternational journal of molecular sciences · 2024Article
- Diagnosis and comprehensive treatment of a glucagonoma in a patient with residual intrahepatic metastases postoperatively: A case report and literature review.Oncology letters · 2024Article
- Article
- Insulinoma as a cause of seizure-like activity and spontaneous hypoglycaemia.BMJ case reports · 2023Article
- Epidemiological trends for functional pancreatic neuroendocrine tumors: A study combining multiple imputation with age adjustment.Frontiers in endocrinology · 2023Article
- Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors.BMC surgery · 2022Article
- Review
- Survival Benefit of Primary Tumor Resection Among Elderly Patients with Pancreatic Neuroendocrine Tumors.World journal of surgery · 2021Article
- Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies.World journal of gastroenterology · 2021Review
- Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes.Expert opinion on pharmacotherapy · 2021Article
- Long-Term Outcomes after Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors: Results from the US Neuroendocrine Study Group.Neuroendocrinology · 2021Article
- Surgical Management of Neuroendocrine Tumours of the Pancreas.Journal of clinical medicine · 2020Review
- Surgical management of primary pancreatic neuroendocrine tumors.Journal of gastrointestinal oncology · 2020Review
- Comparison of prognosis between observation and surgical resection groups with small sporadic non-functional pancreatic neuroendocrine neoplasms without distant metastasis.Journal of gastroenterology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Neuroendocrine tumors (NETs) [carcinoids, pancreatic neuroendocrine tumors (pNETs)] are becoming an increasing clinical problem because not only are they increasing in frequency, but they can frequently present with advanced disease that requires diagnostic and treatment approaches different from those used in the neoplasms that most physicians are used to seeing and treating. In the past few years there have been numerous advances in all aspects of NETs including: an understanding of their unique pathogenesis; specific classification systems developed which have prognostic value; novel methods of tumor localization developed; and novel treatment approaches described. In patients with advanced metastatic disease these include the use of newer chemotherapeutic approaches, an increased understanding of the role of surgery and cytoreductive methods, the development of methods for targeted delivery of cytotoxic agents, and the development of targeted medical therapies (everolimus, sunitinib) based on an increased understanding of the disease biology. Although pNETs and gastrointestinal NETs share many features, recent studies show they differ in pathogenesis and in many aspects of diagnosis and treatment, including their responsiveness to different therapies. Because of limited space, this review will be limited to the advances made in the management and treatment of patients with advanced metastatic pNETs over the past 5 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.